Table 3.
Results of cardiopulmonary exercise testing among participants who completed the trial
| Placebo (n = 54) |
Rosiglitazone (n = 54) |
P-value between groups at end-of-study | |||||
|---|---|---|---|---|---|---|---|
| Baseline | End-of-study | P-value within group | Baseline | End-of-study | P-value within group | ||
| Primary outcome | |||||||
| VO2 (mL/kg-FFM/min) | 28.0 (7) | 27.6 (6.6) | 0.49 | 26.9 (6.3) | 26.1 (7) | 0.06 | 0.26 |
| At rest | |||||||
| Heart rate | 75 (11.1) | 75 (13.8) | 0.84 | 73 (12.6) | 76 (14.2) | 0.08 | 0.92 |
| Blood pressure | |||||||
| Systolic, mmHg | 148 (22.5) | 145 (23.1) | 0.25 | 151 (25.8) | 143 (20.0) | 0.07 | 0.87 |
| Diastolic, mmHg | 83 (11.7) | 80 (11.3) | 0.08 | 84 (13.1) | 78 (9.6) | 0.004 | 0.49 |
| Peak exercise | |||||||
| Heart rate | 152 (21.2) | 150 (23.3) | 0.36 | 144 (24.5) | 142 (23.9) | 0.29 | 0.09 |
| Blood pressure | |||||||
| Systolic, mmHg | 191 (28.7) | 190 (24.8) | 0.92 | 195 (29.2) | 194 (25.6) | 0.75 | 0.41 |
| Diastolic, mmHg | 91 (19.8) | 95 (25.1) | 0.76 | 93 (17.9) | 91 (19.4) | 0.41 | 0.52 |
| VO2 (mL/min) | 1835 (490) | 1815 (503) | 0.55 | 1788 (567) | 1736 (592) | 0.07 | 0.46 |
| VO2 (mL/kg/min) | 19.3 (5.5) | 19 (5.2) | 0.29 | 18.4 (4.6) | 17.3 (5.0) | 0.0003 | 0.06 |
All values reported as mean (standard deviation); VO2, oxygen consumption; mL, millilitre; kg, kilogram; FFM, fat-free mass.